Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adcetris and gemcitabine in relapsed/refractory Hodgkin lymphoma
NCT01780662Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2013
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of brentuximab vedotin in Hodgkin lymphoma (HL), sponsored by National Cancer Institute. Started Jan 2013; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01780662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01780662.